The following therapeutic strategies are accepted or are under investigation:
In practise only beta-interferon has been shown to alter the activity of the disease and possibly to reduce disability. Intravenous immunoglobulin and glatitramer acetate are promising alternatives.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.